Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

pamapimod

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Pamapimod (PAM) is a novel selective p38 mitogen-activated protein (MAP) kinase inhibitor proved to be effective in rheumatoid… Expand
Is this relevant?
Review
2013
Review
2013
Background The safety profile of the protein kinase inhibitors (PKI) in trials for Rheumatoid Arthritis (RA) is unknown… Expand
Is this relevant?
2011
2011
The development of a new series of p38α inhibitors resulted in the identification of two clinical candidates, one of which was… Expand
Is this relevant?
2011
2011
OBJECTIVE This study investigated the pharmacokinetics, excretion, and metabolism of pamapimod following a single oral dose in… Expand
Is this relevant?
Highly Cited
2010
Highly Cited
2010
OBJECTIVE To determine the efficacy and safety of pamapimod in adult patients with active rheumatoid arthritis (RA) who had an… Expand
Is this relevant?
2010
2010
This study evaluated the potential pharmacokinetic interaction of pamapimod, a p38 mitogen-activated protein kinase inhibitor… Expand
  • figure 1
  • figure 2
Is this relevant?
2010
2010
BACKGROUND AND PURPOSE A main challenge in the therapy of osteoarthritis (OA) is the development of drugs that will modify the… Expand
Is this relevant?
Review
2010
Review
2010
Methotrexate alone or in combination with other agents is the standard treatment for moderate-to-severe rheumatoid arthritis. As… Expand
Is this relevant?
Highly Cited
2009
Highly Cited
2009
OBJECTIVE To determine the efficacy and safety of pamapimod (a selective inhibitor of the alpha-isoform of p38 MAP kinase) as… Expand
Is this relevant?
2008
2008
P38alpha is a protein kinase that regulates the expression of inflammatory cytokines, suggesting a role in the pathogenesis of… Expand
  • figure 1
  • table 2
  • table 1
  • figure 2
  • table 3
Is this relevant?